AlphaVax, Inc. (AVX)

We are a privately-held, clinical-stage biopharmaceutical company, that has used its proprietary alphavaccine vector platform technology to generate a portfolio of seven vaccine candidates for infectious disease prevention and cancer immunotherapy. Additional candidates for bio-defence applications have also been developed.

Four alphavaccine candidates, targeting human cytomegalovirus, influenza A virus, prostate cancer and HIV-1, have been evaluated in five Phase 1 clinical trials. More recently, AVX has focused its efforts in an additional three clinical trials with two additional vaccine candidates (one in breast cancer, two in GI cancers) in the development of immunotherapeutic vaccines for the treatment of various cancers. From these latter efforts, AVX has successfully progressed the development of its proprietary alphavaccine technology, to create new, potentially first-in-class, vaccines that engage the patient’s immune system both to recognize and fight off various cancers.

Results from AVX’s first trial evaluating its CEA alphavaccine in patients with Stage IV colon cancer showed the vector technology was able to “break self-tolerance” and a trend for enhanced survival in patients with CEA-specific T cell responses.